Solventum (SOLV) has attracted attention after investors grew concerned about possible AI disruption in its Health Information Systems segment, even as the company reports positive organic growth, deleveraging and ongoing free cash flow generation.

AI disruption concerns have weighed on sentiment at times, but Solventum’s share price has still delivered a 90 day share price return of 18.09% and a 1 year total shareholder return of 8.24%, with the stock now trading at $81.01.

If AI in healthcare IT has your attention, it is worth widening your watchlist using Simply Wall St’s screener for 39 healthcare AI stocks

With Solventum reporting revenue of US$8.26b, net income of US$1.43b and an indicated intrinsic value discount of 71%, a key question is whether recent gains leave more room to run or whether the market is already pricing in future growth.

Most Popular Narrative: 1.4% Undervalued

Solventum’s most followed narrative puts fair value at $82.15, only slightly above the last close at $81.01, so the valuation gap is narrow and highly assumption driven.

The company's new product innovation pipeline (notably in Negative Pressure Wound Therapy, advanced wound care, sterilization, and digital health solutions such as autonomous coding) is gaining traction, positioning Solventum to benefit from rising global demand for technologically advanced healthcare equipment, ultimately supporting future topline and earnings growth.

Curious how modest revenue growth, thinner margins and a higher future P/E are all stitched together into that fair value story? The key assumptions sit beneath the headline, and the tension between shrinking earnings and a richer earnings multiple is what really defines this narrative.

Result: Fair Value of $82.15 (UNDERVALUED)

However, the story could change quickly if separation and ERP execution issues hit margins harder than expected, or if SKU rationalization weighs more heavily on reported growth.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment split between AI disruption risks and growth opportunities, this is a moment to move quickly and test the narrative against the numbers for yourself by reviewing the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop here, you could miss stocks that better fit your goals. Take a few minutes to scan other opportunities that match your style.

• Target potential mispricings by reviewing companies highlighted in the 49 high quality undervalued stocks.
• Prioritize resilience and capital strength by screening for businesses in the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for under-the-radar opportunities by checking the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.